Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 800 of 994 entries
View as:

A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)

Phase: N/A Priority: Normal
NCT ID: NCT00936650 Org: User:
Start: 11/30/99 End: 06/30/01 Due: 06/30/02

A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05913115 Org: User:
Start: 06/12/17 End: 06/19/18 Due: 06/19/19

Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels

Phase: N/A Priority: Normal
NCT ID: NCT00113958 Org: User:
Start: - End: - Due: -

Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

Phase: N/A Priority: Normal
NCT ID: NCT04058028 Org: User:
Start: 02/19/20 End: 07/25/23 Due: 07/25/24

SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

Phase: N/A Priority: Normal
NCT ID: NCT00418938 Org: User:
Start: 11/01/06 End: 04/01/13 Due: 04/01/14

Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT00322439 Org: User:
Start: 05/01/06 End: 02/08/13 Due: 02/08/14

Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension

Phase: N/A Priority: Normal
NCT ID: NCT02641353 Org: User:
Start: 01/05/16 End: 02/27/16 Due: 02/27/17

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT05669599 Org: User:
Start: 01/18/23 End: 01/02/26 Due: 01/02/27

Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00101894 Org: User:
Start: 12/31/04 End: 12/31/11 Due: 12/31/12

Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)

Phase: N/A Priority: Normal
NCT ID: NCT02575833 Org: User:
Start: 11/23/15 End: 04/13/17 Due: 04/13/18

Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis

Phase: N/A Priority: Normal
NCT ID: NCT01733316 Org: User:
Start: 01/31/13 End: 07/10/17 Due: 07/10/18

Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)

Phase: N/A Priority: Normal
NCT ID: NCT00115414 Org: User:
Start: - End: - Due: -

A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.

Phase: N/A Priority: Normal
NCT ID: NCT00002126 Org: User:
Start: - End: - Due: -

A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00037518 Org: User:
Start: 04/30/01 End: - Due: -

Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00479817 Org: User:
Start: 07/05/07 End: 12/09/19 Due: 12/09/20

A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH

Phase: N/A Priority: Normal
NCT ID: NCT03818607 Org: User:
Start: 01/22/19 End: 07/12/22 Due: 07/12/23

Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Phase: N/A Priority: Normal
NCT ID: NCT06054113 Org: User:
Start: 07/22/24 End: 07/21/27 Due: 07/21/28

AMG 595 First-in-Human in Recurrent Gliomas

Phase: N/A Priority: Normal
NCT ID: NCT01475006 Org: User:
Start: 02/29/12 End: 04/30/16 Due: 04/30/17

Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

Phase: N/A Priority: Normal
NCT ID: NCT05368103 Org: User:
Start: 04/27/22 End: 01/26/24 Due: 01/26/25

Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia®) in Routine Clinical Practice

Phase: N/A Priority: Normal
NCT ID: NCT01652690 Org: User:
Start: 06/26/12 End: 05/15/15 Due: 05/15/16

Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)

Phase: N/A Priority: Normal
NCT ID: NCT00773734 Org: User:
Start: 09/01/08 End: 05/20/15 Due: 05/20/16

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Phase: N/A Priority: Normal
NCT ID: NCT00770536 Org: User:
Start: 01/31/09 End: 06/30/15 Due: 06/30/16

Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00626704 Org: User:
Start: 11/30/07 End: 03/31/11 Due: 03/31/12

Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis

Phase: N/A Priority: Normal
NCT ID: NCT00872729 Org: User:
Start: 05/31/09 End: 10/31/09 Due: 10/31/10

Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00984815 Org: User:
Start: 09/30/09 End: 07/31/11 Due: 07/31/12